Richard D Lopez, MD

Associate Professor of Medicine
Campus mail Box 3961 Med Ctr, Durham, NC 27710
Phone (919) 668-1000
Email address richard.lopez@duke.edu

Education and Training

  • Resident, Medicine, Stanford University School of Medicine, 1990 - 1991
  • Intern, Medicine, Stanford University School of Medicine, 1989 - 1990
  • M.D., Stanford University, 1989

Publications

Lopez, R. D., S. Xu, B. Guo, R. S. Negrin, and E. K. Waller. “CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies..” Blood 96, no. 12 (December 1, 2000): 3827–37.

PMID
11090067
Scholars@Duke

Sun, Q., R. L. Burton, A. M. Ship, W. P. Vaughan, D. E. Salzman, R. Lopez, M. A. Carabasi, B. Pohlman, and K. G. Lucas. “Adoptive immunotherapy with allogeneic EBV CTL for organ transplant patients with ebv induced lymphoproliferative disease.” Blood 96, no. 11 PART II (December 1, 2000).

Scholars@Duke

Sherman, M. A., V. H. Secor, S. K. Lee, R. D. Lopez, and M. A. Brown. “STAT6-independent production of IL-4 by mast cells..” Eur J Immunol 29, no. 4 (April 1999): 1235–42. https://doi.org/10.1002/(SICI)1521-4141(199904)29:04<1235::AID-IMMU1235>3.0.CO;2-0.

PMID
10229091
Full Text

Lopez, R. D., N. Poloso, R. S. Negrin, S. Xu, and E. K. Waller. “Engagement of CD2/LFA-2 on activated human peripheral blood T cells results in an IL-12-dependent resistance to Activation-Induced Cell Death (AICD) in γδ T cells.” Faseb Journal 12, no. 5 (March 20, 1998).

Scholars@Duke

Margulies, D. H., R. Lopez, L. F. Boyd, and J. McCluskey. “Engineering soluble major histocompatibility molecules: why and how..” Immunol Res 6, no. 1–2 (1987): 101–16.

PMID
3114395
Scholars@Duke

Pages